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Abstract: 35 
Background:  The effects of inflammation on nutritional rehabilitation after starting 36 
antiretroviral therapy (ART) are not well understood. We assessed the relationship between 37 
inflammation and body composition among patients enrolled in the Nutritional Support for 38 
African Adults Starting Antiretroviral therapy (NUSTART) trial in Tanzania and Zambia from 39 
2011-2013. 40 
 41 
Methods: HIV-infected, ART-eligible adults with body mass index (BMI) < 18.5 kg/m2 enrolled 42 
in the NUSTART trial were eligible for this study.  Anthropometric and body composition data 43 
were collected at recruitment and  6 and 12 weeks post-ART and C-reactive protein (CRP) was 44 
measured at recruitment and 6 weeks.  The relationships between CRP and body composition 45 
were assessed using multiple regression.   46 
 47 
Results: Of 1815 trial participants, 838 (46.2%) had baseline and 6 week CRP measurements. 48 
Median age was 36 years, 55% were females, and median CD4 count was 135 cells/µL.  A one-49 
log reduction in CRP at 6 weeks was associated with increased mid-upper-arm circumference 50 
(0.45 cm; 0.30, 0.61), calf circumference (0.38 cm; 0.23, 0.54), waist circumference (0.98 cm; 51 
0.59, 1.37), BMI (0.37 kg/m2; 0.24, 0.50), fat-free mass (0.58 kg; 0.26, 0.91), but not with fat 52 
mass (0.09 kg; -0.17, 0.34). Fat-free mass gains persisted at 12 weeks and were more closely 53 
associated with 6 week CRP values than with baseline values.   54 
 55 
Conclusions: Reduction in CRP shortly after ART initiation was associated with higher fat-free 56 
mass gains. Further studies are warranted to determine whether interventions to reduce systemic 57 
inflammation will enhance the gains in fat-free mass.  58 
 59 
Key Words: HIV, inflammation, body composition, malnutrition, antiretroviral therapy 60 
INTRODUCTION 61 
Infection with Human Immunodeficiency Virus (HIV) continues to be a major public health 62 
problem in Sub-Saharan Africa. Despite efforts to promote early diagnosis and treatment 63 
initiation before the onset of advanced disease, over a third of HIV-infected patients initiate 64 
antiretroviral therapy (ART) after developing malnutrition (i.e., a body mass index [BMI] <18.5 65 
kg/m2) and early mortality in this group is exceedingly high.(1, 2) Prior studies in Africa 66 
investigating the effects of nutritional supplementation in the early ART period have not shown a 67 
mortality benefit, and some supplements may actually produce a  disproportionate increase in fat 68 
mass.(3, 4)  A greater recovery of lean mass, as opposed to fat mass, during the early HIV 69 
treatment period may improve survival and reduce the long-term risk of developing chronic 70 
diseases, but the factors influencing lean mass gains among malnourished adults starting ART 71 
are poorly understood. (5) 72 
 73 
Malnutrition and HIV infection are accompanied by high levels of systemic inflammation, due in 74 
part to unchecked viremia, reduced mucosal defenses, and opportunistic infections.(6-8) In 75 
advanced HIV infection, an elevated rate of protein turnover and inappropriately low muscle 76 
protein synthesis prevent weight gain despite sufficient intake of calories and protein.(9-11) With 77 
the initiation of ART and suppression of viremia, systemic inflammation normalizes to varying 78 
degrees, with a concomitant reduction in resting metabolic expenditures and improved weight 79 
gain in most undernourished patients.(12, 13) However, abnormalities in factors related to body 80 
mass partitioning, such as an elevated rate of lipolysis, can persist in some patients despite viral 81 
suppression and may have effects on subsequent nutritional rehabilitation.(14) In prior studies, 82 
aggressive parenteral nutrition in critically ill patients did not markedly improve lean body 83 
mass,(15) and weight gain during treatment for pulmonary tuberculosis was primarily due to gains 84 
in adipose tissue rather than lean mass. (16) 85 
 86 
We hypothesized that a failure to normalize systemic inflammation after starting ART impairs 87 
recovery of lean mass and biases weight gain towards adipose tissue deposition. Using data from 88 
malnourished HIV-infected patients enrolled in a nutritional supplementation trial in Tanzania 89 
and Zambia, we analyzed the relationships between C-reactive protein (CRP) and fat and fat-free 90 
mass immediately before and during first 12 weeks of ART.   91 
 92 
METHODS 93 
This study was conducted as part of the Nutritional Support for Africans Starting Antiretroviral 94 
Therapy (NUSTART) trial (registration # PACTR201106000300631), a randomized, double 95 
blind, controlled trial of a lipid-based nutritional supplement (LNS; prepared by Nutriset, 96 
Malauney, France) in 1815 malnourished HIV-infected patients starting ART in Mwanza, 97 
Tanzania and Lusaka, Zambia. The study was conducted between August 2011 and December 98 
2013. NUSTART participants were randomized to receive either the LNS alone (control arm) or 99 
fortified with additional vitamins and minerals (intervention arm; LNS-VM) in a two-stage 100 
nutritional intervention designed to mimic standard protocols for management of severe 101 
malnutrition in young children. From recruitment until 2 weeks after starting ART, participants 102 
received a low calorie (30 g) LNS, and during weeks 2-6 of ART participants received a high 103 
calorie (250 g or ~1400 kcal/d) LNS. Trial inclusion criteria were 18 years of age or older, ART-104 
naive except for standard regimens to prevent maternal-to-child HIV transmission, BMI < 18.5 105 
kg/m2, and a CD4 count < 350 cells/µl or WHO stage 3 or 4 disease. Self-reported pregnancy 106 
was an exclusion criterion. In separate analysis LNS-VM compared to LNS did not increase fat 107 
mass or fat-free mass at 12 weeks of ART. 108 
 109 
NUSTART participants underwent detailed body composition and laboratory studies as part of 110 
an intensive visit schedule. After recruitment, patients came to the clinic weekly until the start of 111 
ART, and again at weeks 1, 2, 4, 6, 8, and 12 after starting ART. Height was measured at 112 
recruitment using a stadiometer fixed to the wall and weight at each visit using a digital balance. 113 
At recruitment, 2, 6, and 12 weeks after starting ART patients underwent additional 114 
anthropometric evaluation. Waist circumference, mid-upper arm circumference (MUAC), hip 115 
and calf circumferences were measured using a flexible tape, and triceps and sub-scapular 116 
skinfold thickness using a caliper in Lusaka only. All measurements were done in triplicate and 117 
the median value was recorded for analyses. Participants also underwent bioelectrical impedance 118 
analysis (BIA) to estimate fat mass and fat-free mass (Tanita, Tokyo, Japan).  Venous blood 119 
samples were taken at all scheduled visits for laboratory analyses.  Serum CRP was measured at 120 
recruitment and week 6 by ELISA (AssayPro, St. Charles, MO, USA), and hemoglobin was 121 
measured by Hemocue and CD4 count by local central clinical services at recruitment. We did 122 
not determine viral loads due to the limited availability of testing at our sites, the high cost, and 123 
because testing is not routinely available for clinical care in these settings. Furthermore, while 124 
providers at clinical sites recorded their diagnoses of suspected opportunistic infections, the 125 
diagnostic capacity was very limited and confirmatory testing was often not available, and 126 
therefore these data were not included in this analysis. 127 
Sample size 128 
As part of the main study, we  recruited 1876 patients (17).This number was sufficient to detect, at 129 
5% significance, 90% power and 25% attrition by 12 weeks due to death or loss to follow-up, 130 
differences of 0.18 of a standard deviation in secondary continuous outcomes measured at 12 131 
weeks. Since this was part of the secondary analyses we did calculate sample size a priori   132 
 133 
Analyses were conducted using Stata 12.1 and R-software 3.0.2 (www.r-project.org). 134 
Demographics and clinical characteristics of the cohort were presented as percentages or 135 
medians with interquartile ranges (IQR). Participants included in the analysis cohort versus those 136 
deceased/lost prior to 6 weeks after starting ART or without complete laboratory values were 137 
compared using the Kruskal-Wallis and Chi-square tests. CRP and body composition 138 
measurements were compared pairwise across baseline and 6 week, and baseline and 12 week, 139 
time points using the Wilcoxon signed-rank test. 140 
 141 
The primary analysis for this paper assessed the relationship between the change in CRP from 142 
baseline (pre-ART) to 6 weeks post-ART and the change in anthropometric and bioelectric 143 
impedance measurements over the same period using linear regression. CRP was log-144 
transformed while the anthropometric and BIA outcome measurements remained on a linear 145 
scale. Models were adjusted for age, sex, CD4+ count, hemoglobin, treatment arm, country, and 146 
whether the subject was receiving treatment for tuberculosis before starting ART. Hemoglobin 147 
was missing for 8% of cases and was multiply imputed. To account for possible non-linear 148 
associations, continuous variables were modeled using restricted cubic splines with 4 knots. We 149 
also adjusted for the number of days between enrollment and ART initiation to reduce bias 150 
associated with longer pre-ART periods on supplement.  151 
 152 
A second analysis assessed the effect of changes in CRP at 6 weeks with body composition at 12 153 
weeks to determine whether CRP measurements during the LNS intervention predicted longer 154 
term nutritional status after the intervention ended. Using linear regression models, we first 155 
tested for a three-way interaction effect between CRP at enrollment, 6 weeks, and the 156 
intervention arm, but the interaction term was not statistically significant in any of the models 157 
(p>0.10 for all except calf circumference [p=0.08]). We then modeled a two-way interaction 158 
between CRP values and included the intervention arm as an additive effect. The regression 159 
coefficients for baseline and 6 week columns represent the average difference in 12 week body 160 
composition for a one-log difference around the median baseline and 6 week log-CRP values, 161 
respectively.  Models were adjusted for age, sex, CD4+ count, hemoglobin, treatment for 162 
tuberculosis, site, and the number of days between enrollment and ART initiation, and 163 
continuous variables were modeled using restricted cubic splines with 4 knots.  164 
 165 
The NUSTART trial was conducted according to guidelines laid down in the Declaration of 166 
Helsinki and all procedures were approved by the ethics committees of the London School of 167 
Hygiene and Tropical Medicine, the University of Zambia, and the National Institute for Medical 168 
Research, Tanzania. All patients provided written or thumbprint informed consent. 169 
 170 
RESULTS 171 
838 NUSTART participants survived beyond 6 weeks of ART and had serum CRP 172 
measurements performed at baseline and 6 weeks post-ART. The analysis cohort was 55% 173 
female with a median age of 36 years (IQR 30, 42), median pre-ART CD4+ T-cell count of 135 174 
cells/µl (IQR 63, 225), and median BMI of 16.8 kg/m2 (IQR 15.9, 17.6) (Table 1). Participants 175 
were equally distributed between the intervention and control arms, with a higher percentage 176 
(59%) enrolled in Lusaka (similar to the full cohort). Among those not included in the analysis 177 
cohort, 340 had died at 12 weeks, 156 had withdrawn or were lost to follow-up, and the 178 
remaining 481 alive at 12 weeks either did not have a baseline or 6 week CRP measurement 179 
(Table 2). In comparison to the analysis cohort, the excluded participants were more likely to be 180 
male, younger, and had a lower median CD4+ T cell count and lower median BMI (p<0.01 for 181 
all). 182 
 183 
Table 3 shows median serum CRP at baseline and 6 weeks of ART, and anthropometric and BIA 184 
measurements at baseline and 6 and 12 weeks. Median CRP only decreased from 38.2 mg/l (IQR 185 
8.9, 124) to 34.8 mg/l (IQR 12.2, 94.5) from baseline to six weeks, which was not statistically 186 
significant (p=0.91). The paired change from baseline to 6 weeks of ART for all of the body 187 
composition measurements was statistically significant (p<0.001 for all), and the paired change 188 
from 6 to 12 weeks was also significant (p<0.01 for all). 189 
 190 
The intra-individual changes in serum CRP from baseline to 6 weeks were inversely associated 191 
with changes in several of the body composition measurements over the same period (Table 4). 192 
A one-log reduction in CRP was associated with a 0.37 kg/m2 increase in BMI, a 0.45 cm 193 
increase in mid-upper arm circumference, a 0.98 cm increase in waist circumference, and 0.58 kg 194 
increase in fat-free mass at 6 weeks of ART (p<0.001 for all). Other anthropometric 195 
measurements were also inversely related to the change in CRP with the exception of BIA fat 196 
mass. These relationships appeared non-linear. While greater reductions in log-CRP were 197 
generally associated with greater body composition changes, a failure to reduce log-CRP or a 198 
rise in log-CRP on ART was generally associated with little change (Figure). The relationships 199 
of CRP at baseline and 6 weeks with body composition at 12 weeks were assessed using linear 200 
regression models incorporating baseline and 6 week values, in addition to a two-way interaction 201 
term between CRP values (Table 5). For the purpose of calculating the effects on body 202 
composition, the model for baseline CRP was adjusted to a median log-CRP value of 3.5, and the 203 
model for 6-week CRP was adjusted to a median log-CRP of 3.6. A one-log higher CRP at 204 
baseline was significantly associated with lower mid-upper arm and waist circumference at 12 205 
weeks. However, a one-log higher 6- week CRP was significantly associated with lower BMI, 206 
mid-upper arm, waist, hip and calf circumference, and triceps skinfold thickness at 12 weeks. 207 
The relationship between 6 week CRP and 12 week BIA fat-free mass approached significance 208 
(p=0.06), while there was little evidence of an association of CRP with 12 week scapular 209 
skinfold thickness and BIA fat mass.  210 
 211 
Due to the complicated nature of interaction effects, we summarized the statistical models of the 212 
combined effect of enrollment and week 6 log-CRP values on the change in 12 week body 213 
composition measurements using heat maps (Supplementary Figure). In these figures, deeper 214 
shades of blue represent larger increases in body composition measurements at 12 weeks 215 
corresponding to a pair of enrollment (x-axis) and week 6 (y-axis) log-CRP values, while deeper 216 
shades of violet represent smaller increases (or negative changes in some variables). The change 217 
in CRP was associated only with mid-upper arm, waist and hip circumference and triceps 218 
skinfold thickness (p<0.05), and approached significance for BMI (p=0.05; p-values refer to the 219 
effect of the two-way interaction term [log-CRP at enrollment and week 6] on outcome 220 
measurements). In general, larger increases in lean body mass metrics were seen in patients with 221 
moderate-to-high baseline CRP and lower 6 week CRP. 222 
 223 
DISCUSSION 224 
In this study of undernourished HIV-infected patients starting ART, we found that a failure to 225 
reduce excessively high levels of CRP in the early weeks following treatment initiation is 226 
associated with failure to accrue lean mass as measured by both anthropometry and BIA.  227 
Furthermore, the accumulation of adipose tissue did not appear dependent on CRP reduction, 228 
suggesting that weight gain in the setting of uncontrolled inflammation may actually represent an 229 
unhealthy shift towards adiposity, with potential consequences for metabolic disease in the 230 
future. These findings suggest the monitoring of inflammatory biomarkers in undernourished 231 
ART patients during the early treatment period, and additional interventions to identify and treat 232 
sources of inflammation, could improve the nutritional and other health outcomes of this 233 
population. 234 
 235 
Restoring individuals with advanced HIV disease and malnutrition to health requires both the 236 
recovery of effective immune protection and the rebuilding of adequate stores of metabolically 237 
active muscle and other lean tissues.(18) While the initiation of ART by undernourished HIV-238 
infected adults is usually accompanied by weight gain to varying degrees, the composition of the 239 
newly deposited tissue is also an important factor in nutritional rehabilitation and the 240 
normalization of metabolic processes. Prior studies in diverse HIV-infected populations have 241 
found mixed effects of ART on body composition, with some showing no effect on fat and lean 242 
mass, and others suggesting that ART may lead to preferential increases in lean or fat mass.(4, 243 
19-21) However, the factors responsible for this heterogeneous response have not been 244 
previously explored in detail.  245 
 246 
Our baseline and follow-up levels of CRP were higher than those reported from studies in 247 
resource-rich settings and may reflect to the combination of untreated viremia, secondary 248 
infections related to immunosuppression or local factors (e.g., parasites), and enteropathy related 249 
to both HIV infection and malnutrition.(6-8) HIV infection depletes lymphoid cells in the 250 
gastrointestinal mucosa integral to defense against bacterial, fungal, and parasitic pathogens, and 251 
impairs tight junctions between epithelial cells, resulting in altered intestinal integrity and 252 
increased translocation of microbes from the intestinal lumen to the circulation.(22-26) Increased 253 
microbial translocation is posited as a major contributor to elevated, chronic inflammation in 254 
HIV-infected individuals, which is likely compounded in the setting of chronic malnutrition due 255 
to similar impairments in intestinal mucosal integrity and the adaptive immune response in the 256 
gut.(6-8, 27) 257 
 258 
Our observation that a higher CRP level is associated with lower lean mass gains may explain 259 
the finding in prior nutritional supplementation trials that some patients gained no weight or 260 
mainly fat mass during early ART, which has also been reported in patients with similar 261 
proinflammatory states such as tuberculosis, severe trauma and cancer .(15, 16),(28) and indicates 262 
that   across the spectrum of infectious and non-infectious diseases, inflammation may be a key 263 
determinant of nutritional depletion and recovery.  264 
Elevated circulating inflammatory cytokines such as TNF-alpha and interleukin-6 are associated 265 
with reduced muscle protein synthesis and deposition, and may stimulate apoptosis in muscle 266 
cells precursors, suggesting that lack of lean mass gain associated with high inflammation may 267 
actually be due to failure of protein synthesis rather than excessive protein breakdown.(9, 10) The 268 
finding that inflammation and lean mass recover are closely linked will be important for 269 
interpreting findings of future nutritional intervention trials in low-income settings, and it may be 270 
the case that any meaningful effects of nutritional interventions on lean mass will depend on first 271 
reducing inflammation. Of note, a recent trial in Ethiopia found that that presence of persistent 272 
HIV-1 viremia at 3 months was associated with preferential fat mass gain, while viral 273 
suppression was associated with lean mass gain. (21)  274 
 275 
In the present study, we noted that CRP levels were not closely associated with 6 or 12 weeks 276 
post-ART measurements of fat mass, which may indicate that the accrual of fat mass is driven by 277 
other factors independent of inflammation.  In higher BMI populations, CRP is positively 278 
associated with fat mass. (29) A similar relationship between fat mass and CRP was not observed 279 
in our patients; and we hypothesize that any contribution of adipose tissue to circulating 280 
inflammatory mediators may have been obscured by the more pronounced effect of advanced 281 
malnutrition and HIV infection on systemic inflammation. However, further work is needed to 282 
understand the directionality of the relationships between inflammation and body fat mass in low 283 
versus normal and high BMI individuals. 284 
 285 
Prior studies in Africa have shown elevated CRP, interleukin-6, and other markers of systemic 286 
inflammation are associated with increased mortality on ART, but there are fewer data on the 287 
link between inflammation and long-term outcomes.(30) As the capacity of health systems to 288 
identify and treat cardiovascular, metabolic and other non-communicable diseases in HIV 289 
patients improves in sub-Saharan Africa, epidemiologic studies are needed to determine how 290 
very high levels of inflammation affect long-term health outcomes. 291 
 292 
In this study we included in the analysis about half of the patients recruited for the trial. Patients 293 
not included in the analysis because of loss to follow-up, or death tended to be those who were 294 
severely malnourished, immunocompromised judged by CD4 count and had higher median CRP. 295 
Although a higher baseline CRP, in the excluded survivors would have potentially resulted in a 296 
large reduction in CRP from zero to 6 weeks, assuming that the patterns of correlation remained 297 
the same, this would probably not have significantly changed the associations given that we 298 
modelled the relation between CRP and body composition parameters on log rather than normal 299 
scale.  300 
  301 
 The strength of our study was the prospective design and large sample size, which permitted the 302 
assessment of longitudinal relationships between CRP and body composition between referral 303 
for ART and 6 and 12 weeks post-ART. The BIA method we used was well suited to clinical 304 
care in Africa and has been shown to correlate well with more complicated radiographic 305 
assessments in healthy patients, but there are fewer data comparing BIA versus DEXA and other 306 
radiographic methods in malnourished, HIV patients.(31) However, a longer follow-up period 307 
may have also provided additional insights on trends of body composition changes during ART 308 
among undernourished patients on ART. Furthermore, our study could not assess the long-term 309 
implications of early changes in body composition on ART. We observed a 0.37 kg/m2 rise in 310 
BMI at 6 weeks in patients with a one-log CRP reduction over the same period, which represents 311 
an approximately 2%-2.5% BMI increase (depending on the baseline BMI value). Prior studies 312 
have shown modest early increases in BMI are clinically important for long-term survival, but 313 
additional studies are warranted to understand how body composition, inflammation, and other 314 
nutritional factors interact to influence health outcomes.(32)  Although additional LNS received 315 
by patients in the trial may have made them different from the rest of HIV population on ART, 316 
this difference would have disappeared a few weeks after starting ART as patients on treatment 317 
regained appetite and started consuming nutritionally diverse food. Thus, these findings can be 318 
generalized to all malnourished HIV-infected patients starting ART. 319 
 320 
 CONCLUSIONS 321 
In conclusion, among HIV-infected adult patients, reductions in CRP over the first six weeks of 322 
ART were associated with higher lean body mass gains; and patients with lower CRP at 6 weeks 323 
continued to have greater lean mass up to 12 weeks. Promoting lean body mass gains in 324 
malnourished HIV patients starting ART is important for nutritional rehabilitation and may 325 
impact long-term survival and chronic disease risk. Future trials should consider interventions 326 
addressing both nutritional recovery and inflammation, to elucidate mechanisms and optimize 327 
outcomes in malnourished patients. Lastly, further studies on the effect of persistent high level of 328 
inflammation as well as fat mass gains on long-term chronic disease risk, including diabetes 329 
mellitus and cardiovascular conditions, are needed in sub-Saharan Africa. 330 
 331 
Figure legends 332 
Figure. Relationship of the change in C-reactive protein and body composition measurements 333 
between baseline and 6 weeks of antiretroviral therapy.   334 
Models adjusted for sex, treatment arm, country, and age, CD4+ count, hemoglobin, and receipt 335 
of anti-tuberculosis therapy at treatment initiation. CRP is log-transformed. Abbreviations: BMI, 336 
body mass index.  337 
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